Engineered immune cells take on Hard-to-Treat brain diseases
NCT ID NCT07341828
First seen Jan 23, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-phase study is testing a new treatment called C-CAR168 for people with severe autoimmune diseases affecting the brain and spinal cord, such as multiple sclerosis and autoimmune encephalitis, that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to target and attack harmful immune cells. The main goal is to check the safety of this approach and find the right dose in a small group of 15 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STIFF PERSON SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.